Switch of AndroidAPS to Commercially Available AID Systems

Switch of Open-source Automated Insulin Delivery System - AndroidAPS to Commercially Available AID Systems in Type 1 Diabetes: the Extension of the CODIAC Study

The aim of the study was to investigate the switch between open-source automated insulin delivery system (OS-AID) - AndroidAPS (AAPS) and commercially available AID systems - Control-IQ (CIQ) and MiniMed 780G (780G) in extended follow-up study.

Inclusion Criteria:

• type 1 diabetes diagnosed >2 years
• ≥ 18 years old
• written informed consent prior to starting study related activity
• previous user of AndroidAPS at least for 3 months

Exclusion Criteria:

• nonadherence to the current treatment regimen
• lactation
• pregnancy
• intending to become pregnant during study
• concomitant therapy influencing glucose metabolism